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Non-small-cell lung cancer (NSCLC) remains by far the major cause of cancer-related death in the Western world in both men and
women. The majority of patients will be diagnosed with metastatic disease, and chemotherapy doublets remain the cornerstone of
treatment for these patients. However, chemotherapy has a minimal impact on long-term survival and prognosis remains poor for
these patients. Further improvement in treatment is likely to require incorporation of novel targeted therapies. Among these agents,
inhibitors of the epidermal growth factor receptor (EGFR) have demonstrated significant activity in the first-, second- or third-line
treatment of NSCLC. The purpose of current paper is to present the evidence for using several proposed molecular biomarkers as a
tool for selection of NSCLC patients for anti-EGFR treatment. According to current data, EGFR mutation status appears to be the
strongest predictor for the selection of NSCLC patients to first-line treatment with EGFR tyrosine kinase inhibitors vs chemotherapy.
Use of other biomarkers remains investigational.
British Journal of Cancer (2011) 105, 1–8. doi:10.1038/bjc.2011.207 www.bjcancer.com
Published online 7 June 2011
& 2011 Cancer Research UK
Keywords: EGFR; immunohistochemistry; gene copy number; mutations; gefitinib; erlotinib
                                              
Chemotherapy has been the backbone of treatment for patients
with advanced non-small-cell lung cancer (NSCLC) for the last
decades; however, it has clearly reached a plateau of activity, and
thus further improvements will require integration of novel
therapies. Among the targeted agents, epidermal growth factor
receptor (EGFR) inhibitors gefitinib and erlotinib are now
established as an option for first-, second- or third-line treatment
(Shepherd et al, 2005; Kim et al, 2008; Mok et al, 2009; Maemondo
et al, 2010; Mitsudomi et al, 2010) or as maintenance treatment
(Cappuzzo et al, 2010a). Furthermore, the addition of cetuximab,
a monoclonal antibody, against the extracellular domain of EGFR
to the vinorelbine/cisplatin doublet resulted in a statistically
significant, but modest, survival prolongation (Pirker et al, 2009).
A subset of patients treated with EGFR inhibitors experience a
clinical benefit and even these patients eventually develop disease
progression. It is clear that we need to identify reliable predictive
factors that will allow for the selection of patients who are most
likely to benefit from a particular agent, while sparing others from
toxicity of ineffective treatments and the health-care systems from
the significant costs of these newer agents. The purpose of the
present paper is to focus on the current evidence for using several
proposed molecular biomarkers as a tool for selection of NSCLC
patients for anti-EGFR treatment.
SEARCH STRATEGY AND SELECTION CRITERIA
A bibliographic search of the Medline database was conducted for
papers published from 1 January 2000 to 1 July 2010, with the
keywords ‘non-small-cell lung cancer’, ‘epidermal growth factor
receptor’, ‘erlotinib’ ‘gefitinib’ and ‘cetuximab’. The search was
limited to articles written in English. When considering chemo-
therapy, targeted therapy or multimodality treatment, only data from
phase III trials or randomised phase II trials were incorporated. The
Medline search was supplemented by a manual search of meeting
abstracts (World Conference on Lung Cancer, European Society of
Medical Oncology Annual Congress, American Society of Clinical
Oncology Annual Meeting, European Lung Cancer Conference) as
well as reference lists of original and review articles. A consensus was
reached among all authors for the manuscript.
POSITIVE PREDICTIVE FACTORS
Protein expression by immunohistochemistry
Association of positive EGFR immunostaining, as determined by
immunohistochemistry (IHC) in NSCLC specimens, with patient
Received 6 January 2011; revised 4 May 2011; accepted 13 May 2011;
published online 7 June 2011
*Correspondence: Dr AG Pallis; E-mail: agpallis@gmail.com
British Journal of Cancer (2011) 105, 1–8
& 2011 Cancer Research UK All rights reserved 0007– 0920/11
www.bjcancer.comsensitivity to EGFR TKI treatment has been studied extensively
with both positive (Cappuzzo et al, 2005; Hirsch et al, 2007) and
negative (Parra et al, 2004) results reported. Four placebo-
controlled phase III trials have evaluated EGFR TKIs as
maintenance (Takeda et al, 2010; Cappuzzo et al, 2010a; Sequential
Tarceva in Unresectable NSCLC (SATURN) and West Japan
Thoracic Oncology Group (WJTOG) 0203 trials), second- or
third-line treatment (Shepherd et al, 2005; Thatcher et al, 2005;
NCIC Clinical Trials Group BR.21 and Iressa Survival Evaluation in
Lung Cancer (ISEL) trials). Another phase III trial, the ATLAS trial
(Kabbinavar et al, 2010), was designed to evaluate the addition of
erlotinib to bevacizumab maintenance in NSCLC patients who
have not progressed after first-line chemotherapy plus bevacizu-
mab. Patients with EGFR-expressing tumours had significantly
higher response rate (RR) in the BR.21 (P¼0.03) and ISEL trials
(8.2 vs 1.5%; P not reported; Tsao et al, 2005; Hirsch et al, 2006). In
three trials (SATURN, BR.21 and ISEL), patients with tumours
showing positive EGFR immunostaining had a significantly
reduced risk of death or progression with TKI treatment vs
placebo (Tsao et al, 2005; Hirsch et al, 2006; Brugger et al, 2009)
with hazard ratios (HRs) of 0.68–0.77 in favour of EGFR TKI
therapy (Table 1). However, it should be noted that in the ISEL
trial, the benefit was of borderline significance (treatment by
biomarker interaction test P¼0.049; Hirsch et al, 2006). The
WJTOG 0203 was a relatively small and negative trial and the lack
of any biomarker published data limits the interpretation and
applicability of the findings of this study. In the ATLAS trial, EGFR
IHC analysis had no predictive value for progression-free survival
(PFS) (Johnson et al, 2009). The cut-off point analyses of two large
placebo-controlled trials in the second- and third-line setting
revealed that the originally proposed criterion to define EGFR
positivity (10% of cells with any staining intensity) had the best
predictive discrimination (Hirsch et al, 2008).
Two phase III trials that compared TKIs with chemotherapy
either in first-line (Mok et al, 2009) or second-line setting (Kim
et al, 2008) reported biomarker data with tumour EGFR
immunostaining. The Iressa Pan-Asian Study (IPASS) study
randomly assigned Asian chemo-naive NSCLC patients (never-
smokers or former light smokers with adenocarcinoma) to
gefitinib or to paclitaxel/carboplatin chemotherapy (Mok et al,
2009). This trial met its primary end point of showing non-
inferiority of gefitinib, but furthermore demonstrated its super-
iority compared with chemotherapy for PFS (HR 0.74, Po0.001).
The Iressa NSCLC Trial Evaluating Response and Survival versus
Taxotere (INTEREST) trial was a non-inferiority phase III trial that
compared gefitinib with docetaxel as second-line treatment (Kim
et al, 2008). This study also confirmed that gefitinib was non-
inferior to docetaxel in terms of overall survival (OS) (HR 1.020).
In these trials, using chemotherapy as the comparator, no
predictive value of EGFR IHC analysis was observed for response,
PFS or survival, and EGFR protein expression status-by-treatment
interaction tests were not significant (Fukuoka et al, 2009;
Douillard et al, 2010).
Two phase III trials have assessed the role of monoclonal anti-
EGFR antibody therapy in addition to first-line chemotherapy in
the treatment of NSCLC (Pirker et al, 2009; Lynch et al, 2010). The
FLEX trial investigated the combination of cisplatin/vinorelbine
plus or minus cetuximab, and demonstrated a statistically
significant although modest survival benefit in favour of cetux-
imab in patients with tumours positive for EGFR protein
expression. A second smaller trial, which compared the combina-
tion of a taxane/carboplatin plus or minus cetuximab (BMS-099) in
unselected patients, failed to show a PFS or survival benefit in
favour of the experimental arm. The biomarker analysis did not
reveal any association between EGFR protein expression and
response, PFS or survival (Khambata-Ford et al, 2010).
According to the above studies, EGFR protein positivity is
observed in the vast majority of NSCLC tumour specimens
(ranging from approximately 70 to 90% in most studies), which
makes this marker unlikely to be used in practice for patient
selection. Placebo-controlled phase III trials with EGFR TKIs in the
second- or third-line setting were the only studies indicating some
predictive value of lack of protein expression in selecting patients
who do not benefit from these agents, although its predictive
discrimination did not meet the expectations of a clinically useful
test (i.e., clinically meaningful difference between patient subsets).
Table 1 Survival HRs according to EGFR protein expression in phase III trials with EGFR tyrosine kinase inhibitors
Trial N HR 95% CI P-value
Biomarker by treatment
interaction P-value
BR.21 (Shepherd et al, 2005; Tsao et al, 2005)
Positive 184 0.68 0.49–0.95 0.02 NR
Negative 141 0.93 0.63–1.36 0.70
ISEL (Thatcher et al, 2005; Hirsch et al, 2006)
Positive 264 0.77 0.56–1.08 0.126 0.049
Negative 115 1.57 0.86–2.87 0.140
SATURN (Brugger et al, 2009; Cappuzzo et al, 2010b)
a
Positive NR 0.69 0.58–0.82 o0.0001 NR
ATLAS (Johnson et al, 2009)
a
Positive 191 0.92 0.64–1.32 NR
Negative 67 1.00 0.55–1.82 NR NR
INTEREST (Kim et al, 2008; Douillard et al, 2010)
Positive 284 1.00 0.77–1.29 0.98 0.87
Negative 96 1.00 0.65–1.55 0.99
IPASS (Fukuoka et al, 2009; Mok et al, 2009)
a
Positive 266 0.73 0.55–0.96 0.0243 0.21
Negative 99 0.97 0.64–1.48 0.8932
Abbreviations: ATLAS¼Avastin and Tarceva or Avastin and pLAcebo in patients with NSCLC; CI¼confidence interval; EGFR¼epidermal growth factor receptor; HR¼hazard
ratio; ISEL¼Iressa Survival Evaluation in Lung Cancer; INTEREST¼Iressa NSCLC Trial Evaluating Response and Survival versus Taxotere; IPASS¼Iressa Pan-Asian Study;
NR¼not reported; SATURN¼Sequential Tarceva in Unresectable NSCLC.
aHR for progression-free survival.
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EGFR gene copy number, assessed by fluorescence in situ
hybridisation (FISH), has been tested extensively as a predictive
factor for response and survival benefit from TKI treatment. The
original classification of FISH positivity includes both gene
amplification (rare in NSCLC) and high polysomy (X4 copies of
the EGFR gene in 440% of tumour cell nuclei; Cappuzzo et al,
2005). In placebo-controlled studies (BR.21 and ISEL studies;
Shepherd et al, 2005; Thatcher et al, 2005), high EGFR copy
number was associated with higher response rate and significantly
prolonged OS from EGFR TKI treatment (Tsao et al, 2005; Zhu
et al, 2008; Table 2). Moreover, in the BR.21 study, high EGFR copy
number by FISH was both prognostic for worse survival in
untreated patients (P¼0.025) and predictive of greater survival
benefit in erlotinib-treated patients (P¼0.005). In the ISEL trial,
high EGFR copy was associated with a survival benefit in patients
receiving gefitinib compared with placebo (HR 0.61; P¼0.067),
whereas no benefit was observed in patients with FISH-negative
tumours (HR 1.16; P¼0.417; comparison of HRs high vs low copy
number; P¼0.045; Hirsch et al, 2006). In patients treated with
placebo, high EGFR copy was associated with a numerically shorter
survival, indicating that copy number might also be prognostic. In
the biomarker analysis of the SATURN trial, patients derived a PFS
benefit with erlotinib irrespective of EGFR FISH status in their
tumours (Brugger et al, 2009). Similarly, in the biomarker analysis
of the ATLAS trial, EGFR FISH status had no statistically
significant predictive value for PFS, although HRs for PFS were
numerically different within patient subsets (Table 2; Johnson
et al, 2009).
The FISH EGFR assay had no predictive value for survival in
randomised trials comparing TKI treatment with chemotherapy
(Kim et al, 2008; Mok et al, 2009). In the INTEREST trial, RR was
higher in EGFR FISH-positive patients treated with gefitinib
compared with docetaxel (13.0 vs 7.4%; P¼0.04; Douillard et al,
2010). Overall survival and PFS were similar between the two
treatment arms, irrespectively of EGFR copy number (OS
treatment effect between high and low copy number: HR 1.09
and 0.93, respectively; EGFR copy number status-by-treatment
interaction test; P¼0.52). In the IPASS study, EGFR FISH
positivity was associated with higher response rate and a
borderline PFS benefit from gefitinib when compared with
platinum-based chemotherapy (P¼0.044; Fukuoka et al, 2009).
Placebo-controlled phase III trials of cetuximab in combination
with chemotherapy (FLEX and BMS-099) failed to show an
association between EGFR gene copy number status and clinical
end points, including PFS, OS and RR (O’Byrne et al, 2009;
Khambata-Ford et al, 2010).
A phase II trial was performed with prospective EGFR gene copy
number assessment (Cappuzzo et al, 2007). The trial was not
limited exclusively to patients with EGFR FISH positive tumours.
The biomarker results indicate that PFS and OS benefit in patients
with high EGFR gene copy number in their tumours appears to be
derived from overlapping EGFR mutation positivity.
In summary, EGFR copy number is predictive of survival benefit
from erlotinib or gefitinib in placebo-controlled trials in patients
who failed previous chemotherapy (Tsao et al, 2005; Hirsch et al,
2006). These observations were not confirmed in clinical trials
comparing EGFR TKI treatment with chemotherapy (Kim et al,
2008; Mok et al, 2009), suggesting that the predictive value of
EGFR gene copy number assessment is confined to second/third
line trials with placebo arm as a comparator. At present, EGFR
gene copy number testing is not recommended in the selection of
first- or second-line treatment of advanced NSCLC patients. Data
from phase III trials do not suggest a role for EGFR gene copy
number in predicting benefit from anti-EGFR monoclonal anti-
bodies in NSCLC.
Somatic EGFR mutations
Most somatic mutations of the EGFR gene observed in NSCLC
involve the tyrosine kinase coding domain (exons 18–21).
Discovery of these mutations in tumours from NSCLC patients
was immediately linked with response to gefitinib (Lynch et al,
2004; Paez et al, 2004). In placebo-controlled phase III studies of
Table 2 Survival HRs according to EGFR gene copy number as assessed by FISH in phase III trials with EGFR tyrosine kinase inhibitors
Trial N HR 95% CI P-value
Biomarker by treatment
interaction P-value
BR.21 (Shepherd et al, 2005; Tsao et al, 2005; Zhu et al, 2008)
FISH positive 61 0.43 0.23–0.78 0.0042 0.12
FISH negative 98 0.80 0.49–1.29 0.3525
ISEL (Thatcher et al, 2005; Hirsch et al, 2006)
FISH positive 114 0.61 0.36–1.04 0.067 0.045
FISH negative 256 1.16 0.81–1.64 0.417
SATURN (Brugger et al, 2009; Cappuzzo et al, 2010b)
a
FISH positive 0.69 NR 0.0001 NR
ATLAS (Johnson et al, 2009)
a
FISH positive 87 0.66 0.39–1.13 NR NR
FISH negative 109 1.40 0.86–2.28 NR
INTEREST (Kim et al, 2008; Douillard et al, 2010)
FISH positive 174 1.09 0.78–1.51 0.62 0.52
FISH negative 200 0.93 0.68–1.26 0.64
IPASS (Fukuoka et al, 2009; Mok et al, 2009)
a
FISH positive 249 0.66 0.50–0.88 0.0050 0.0437
FISH negative 157 1.24 0.87–1.76 0.2368
Abbreviations: ATLAS¼Avastin and Tarceva or Avastin and pLAcebo in patients with NSCLC; CI¼confidence interval; EGFR¼epidermal growth factor receptor;
FISH¼fluorescence in situ hybridisation; HR¼hazard ratio; ISEL¼Iressa Survival Evaluation in Lung Cancer; INTEREST¼Iressa NSCLC Trial Evaluating Response and Survival
versus Taxotere; IPASS¼Iressa Pan-Asian Study; NR¼not reported; SATURN¼Sequential Tarceva in Unresectable NSCLC.
aHR for progression-free survival.
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Cappuzzo et al, 2010a), patients with EGFR-mutated tumours had
significantly higher RR compared with patients with wild-type
tumours. In the BR.21 study, both groups derived a survival
benefit (Zhu et al, 2008). In the ISEL study, there were too few
patients with mutations for survival subset analysis (Hirsch et al,
2006), whereas in the SATURN trial, a remarkable PFS benefit
was observed in patients with tumours with EGFR mutations in
the erlotinib arm (HR 0.10; Po0.0001; Brugger et al, 2009).
Similarly, the biomarker analysis of the ATLAS trial reported a
significant benefit in terms of PFS in patients with tumours
bearing EGFR mutations in the erlotinib arm (HR 0.44; Johnson
et al, 2009).
In the INTEREST trial, EGFR mutation-positive patients had
significantly longer PFS (HR 0.16; P¼0.001) and higher RR when
treated with gefitinib when compared with docetaxel (ORR 42.1 vs
21.1%; P¼0.04; Douillard et al, 2010). Patients harbouring EGFR
mutation-positive tumours had longer survival in both gefitinib
and docetaxel groups (median survival 14.2 and 16.6 months,
respectively) than in the overall population (7.6 and 8.0 months,
respectively), and in the population with wild-type EGFR (6.4 and
6.0 months, respectively), indicating that EGFR mutations have a
positive prognostic role. There was no OS difference between
treatment groups according to EGFR mutation status (subset of
patients with mutated tumours, HR¼0.83 vs those with wild-type
EGFR,H R¼1.02, interaction test; P¼0.59; Douillard et al, 2010).
In the IPASS study, patients with EGFR-mutated tumours had
significantly higher RR with gefitinib compared with chemother-
apy (71.2 vs 47.3%; P¼0.0001; Fukuoka et al, 2009). There was also
a striking difference in PFS in patients with EGFR-mutated
tumours treated with gefitinib compared with those treated with
chemotherapy (9.5 vs 6.3 months; HR¼0.48; Po0.001). The
predictive role of EGFR mutation was also demonstrated by the
noteworthy differences in PFS observed in patients with EGFR
mutation-positive or -negative tumours when treated with gefitinib
(9.5 vs 1.5 months). In patients without EGFR TK mutations, PFS
was significantly superior in the group treated with chemotherapy
compared with gefitinib (HR¼2.85; Po0.001; Table 3). The results
of two phase III Japanese trials comparing gefitinib and
chemotherapy as first-line treatment in NSCLC patients exclusively
with tumours harbouring EGFR mutations confirmed improved
outcomes with EGFR TKIs (Maemondo et al, 2010; Mitsudomi
et al, 2010). Similar results were also observed in a Chinese trial
with erlotinib (Zhou et al, 2010).
The NSCLC cell lines harbouring EGFR gene mutations are less
sensitive to monoclonal antibodies than to EGFR tyrosine kinase
inhibitors (Mukohara et al, 2005). In the BMS-099 trial, EGFR
mutation status did not predict benefit from concurrent treatment
with cetuximab and chemotherapy. Survival tended to be longer in
patients with mutated EGFR compared with those with wild-type
EGFR (HR 0.61; P¼0.09). This trend was more apparent in the
chemotherapy group (HR 0.46; P¼0.06) than in the cetuximab
group (HR 0.84; P¼0.66), confirming the prognostic role of EGFR
mutations (Khambata-Ford et al, 2010).
Based on the above mentioned trials, EGFR mutation testing is
now recommended as part of routine care of NSCLC patients to
guide decisions about first-line treatment.
Germline EGFR polymorphisms
Regulatory sequences of the EGFR gene are located within the 50
flanking region, and a highly polymorphic (CA)n repeat is situated
in intron 1 of the gene. In vitro as well as in vivo data indicate that
EGFR transcriptional activity may be influenced by the number of
CA repeats (Gebhardt et al, 2000). Given the association between
gene expression and the number of CA repeats, the efficacy of anti-
Table 3 Survival HRs according to EGFR mutation status in phase III clinical trials with EGFR tyrosine kinase inhibitors
Trial N HR 95% CI P-value
Biomarker by treatment
interaction P-value
BR.21 (Shepherd et al, 2005; Tsao et al, 2005; Zhu et al, 2008)
EGFR mutated 30 0.55 0.25–1.19 0.1217 0.47
EGFR wild-type 176 0.74 0.52–1.05 0.0924
ISEL (Thatcher et al, 2005; Hirsch et al, 2006)
EGFR mutated 26 NR NR NR NR
EGFR wild-type 189
SATURN (Brugger et al, 2009; Cappuzzo et al, 2010b)
a
EGFR mutated 22 0.10 0.04–0.25 o0.0001
EGFR wild-type 199 0.78 0.63–0.96 0.0195
ATLAS (Johnson et al, 2009)
a
EGFR mutated 52 0.44 0.22–0.86 NR NR
EGFR wild-type 295 0.85 0.64–1.13 NR
INTEREST (Kim et al, 2008; Douillard et al, 2010)
EGFR mutated 0.83 0.41–1.67 0.60 0.59
EGFR wild-type NR 1.02 0.78–1.33 0.91
IPASS (Fukuoka et al, 2009; Mok et al, 2009)
a
EGFR mutated 261 0.48 0.36–0.64 o0.001 o0.0001
EGFR wild-type 176 2.85 2.05–3.98 o0.001
WJTOG3405 (Mitsudomi et al, 2010)
a,b 177 0.489 0.336–0.710 o0.0001 NA
NEJ002 (Maemondo et al, 2010)
a,c 230 0.36 0.25–0.51 o0.001 NA
CTONG 0802 (Zhou et al, 2010) 154 0.16 0.10–0.26 o0.0001 NA
Abbreviations: ATLAS¼Avastin and Tarceva or Avastin and pLAcebo in patients with NSCLC; CI¼confidence interval; EGFR¼epidermal growth factor receptor; HR¼hazard
ratio; ISEL¼Iressa Survival Evaluation in Lung Cancer; INTEREST¼Iressa NSCLC Trial Evaluating Response and Survival versus Taxotere; IPASS¼Iressa Pan-Asian Study;
NR¼not reported; NA¼not applicable; SATURN¼Sequential Tarceva in Unresectable NSCLC; TKI¼tyrosine kinase inhibitor.
aHR for progression-free survival.
bGefitinib vs
cisplatin/docetaxel.
cGefitinib vs paclitaxel/carboplatin.
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differences. Two clinical single cohort studies in Asian patients
(Han et al, 2007; Nie et al, 2007) have reported higher response
rates in patients with low CA repeats, and longer time to
progression (HR 0.54, P¼0.014; Han et al, 2007) and OS (20 vs
11 months, RR: 1.89; P¼0.039; Nie et al, 2007). Similarly, an
American study (Liu et al, 2008) reported improved PFS in
patients homozygous for the shorter lengths of CA repeats. This
observation was not confirmed by other studies (Gregorc et al,
2008), and one study reported an association between shorter CA
repeats and poorer survival in the absence of anti-EGFR treatment
(Dubey et al, 2006). Molecular analysis of the SATURN trial did
not confirm predictive value of the number of intron 1 CA repeats
(Brugger et al, 2009).
In addition to EGFR polymorphisms, much interest is focussed
on polymorphisms of the ABCG2 gene, which codes for a
multidrug transporter that has been shown to effectively remove
gefitinib and erlotinib from cells (Li et al, 2007). The ABCG2
421C4A (Q141K) polymorphism results in a glutamine to lysine
substitution in codon 141 and has been associated with increased
toxicity in patients treated with gefitinib (Cusatis et al, 2006) or
with increased concentrations of both gefitinib and erlotinib
(Li et al, 2007; Rudin et al, 2008).
It should be noted that all these data are based on retrospective
review of small, single cohort studies, using different definitions
of key variables such as ‘short’ or ‘long’ intron 1 CA repeats.
Therefore, these studies are unable to properly define the
predictive or prognostic role of these polymorphisms in NSCLC
patients treated with EGFR TKIs.
No data exist about the role of EGFR polymorphisms as
predictors for treatment outcome with anti-EGFR monoclonal
antibodies.
NEGATIVE PREDICTIVE FACTORS
EGFR mutations and resistance to anti-EGFR treatment
One of the mechanisms of primary and acquired resistance in
patients who receive TKI treatment is insertion point mutations in
exon 20 of the EGFR gene. The spectrum of resistant mutations
includes the exon 20 insertion mutants D770_N771 (ins NPG),
D770_(ins SVQ) and D770_(ins G) N771T (Gazdar, 2009). Never-
theless, it should be noted that these mutations are relatively rare,
suggesting that other mechanisms also contribute to primary
resistance to EGFR TKI treatment.
Virtually all patients responding to TKI treatment will inevitably
develop resistance to these agents. A point mutation in the tyrosine
kinase domain (T790M) is found in approximately half of patients
at the time of acquired resistance to EGFR TKI therapy (Gazdar,
2009). This mutation has been observed in a small fraction of cells
in tumours from pretreated patients, believed to be gained through
selective pressure during treatment (Gazdar, 2009). At present,
there are insufficient data to treat patients with tumours having
classical activating exon 19 or 21 mutations that coexist with exon
20 T790M mutations differently than patients without exon 20
mutations. Physicians should be aware that the detection of
resistance mutation may herald the development of clinical
resistance to gefitinib or erlotinib.
K-RAS
Ras plays an important role in the EGFR downstream signalling
pathway, by activating Raf-kinase, MAPK and promoting cell
proliferation (Hynes and Lane, 2005). The K-RAS mutations result
in EGFR-independent activation of MAPK and are mutually
exclusive with EGFR mutations (Pao et al, 2005). These mutations
have been proposed as a mechanism of primary resistance to TKIs
in NSCLC and are observed in B15–30% of NSCLC patients.
Several studies suggest that K-RAS mutations are negative
predictive factors of response to single-agent TKI treatment in
advanced/metastatic NSCLC (Zhu et al, 2008). However, the
molecular analysis of the SATURN trial showed that the benefit
from maintenance erlotinib is similar in patients with and without
K-RAS mutations in their tumours (HR for PFS 0.77 and 0.70,
respectively; Brugger et al, 2009). Although several studies support
that anti-EGFR monoclonal antibodies are not active in colorectal
cancer patients with K-RAS gene mutations, it seems that K-RAS
mutations have no predictive role in NSCLC patients treated with
these agents (O’Byrne et al, 2009; Khambata-Ford et al, 2010),
although limited data are available. At present, there are
insufficient data to use K-RAS mutation status for lung cancer
patient selection to EGFR inhibitor therapy.
Serum proteomic determination of predictive
biomarkers for TKIs
Matrix-assisted laser desorption/ionisation, time-of-flight mass
spectrometry is a potentially powerful and inexpensive tool for
identifying protein signatures in serum. Using this approach, a
TKI prediction algorithm was identified using a training set of 139
samples of serum or plasma (Taguchi et al, 2007). Based on eight
discriminating features and validated in two independent cohorts,
it selectively predicted survival in patients who had received an
EGFR TKI. In cohort 1, there were 67 patients treated with
gefitinib. Survival in the high-risk group was 92 vs 207 days in the
low-risk group with HR of 0.50 and 95% CIs of 0.24–0.78. In
cohort 2, survival was 107 vs 306 days with HR of 0.41 and 95% CIs
0.17–0.63. This serum proteomic classifier has been commercially
developed (Veristrat) and was shown to associate with outcome in
a clinical trial of erlotinib and bevacizumab (Carbone et al, 2010a).
An 11 proteomic feature-based classifier has been developed that
associated with OS in a Cox proportional hazards model in the
training set (P¼0.0006) and also when applied in a blinded test to
patients treated with erlotinib alone in the phase II first-line
monotherapy trial, ECOG 3503 (n¼82, Po0.0001; Salmon et al,
2009). Analysis of the proteomic classifier in the sera from patients
included in the BR.21 trial was recently reported and showed that
this marker had mainly prognostic role (Carbone et al, 2010b).
DISCUSSION
Identification of predictive markers is important for selection of
patients with advanced/metastatic NSCLC who are likely to obtain
a clinical benefit from anti-EGFR treatment. A panel of such
biomarkers has been extensively evaluated in NSCLC patients
treated in clinical trials with these agents. The EGFR expression as
determined by IHC should not be considered as a valid predictive
marker given that published results are conflicting with some
studies showing weak predictive value (mainly placebo-controlled
second/third-line trials), not confirmed in other studies. High
EGFR gene copy number, as assessed by FISH, has been associated
with a survival benefit in the placebo-controlled phase III TKI
trials (Hirsch et al, 2006; Zhu et al, 2008), but had no predictive
value in randomised trials comparing TKI treatment with
chemotherapy (Fukuoka et al, 2009; Douillard et al, 2010). On
the contrary, EGFR mutations were associated with a dramatic
benefit in terms of PFS in both placebo-controlled (Brugger et al,
2009) and chemotherapy-controlled trials (Fukuoka et al, 2009;
Douillard et al, 2010). Furthermore, a recent meta-analysis by
Dahabreh et al (2010) reported that EGFR mutations are predictive
of response to TKIs with a higher sensitivity and specificity
compared with EGFR gene gain, although survival improvement
may not be confined exclusively to patients with tumour
shrinkage. On the basis of the data from clinical trials comparing
Biomarkers of response for EGFR treatment
AG Pallis et al
5
British Journal of Cancer (2011) 105(1), 1–8 & 2011 Cancer Research UKEGFR TKIs with chemotherapy, EGFR-activating mutation status
appears to be the most valid marker for the selection of patients
who would derive the most benefit from TKI treatment.
It is not clear why conflicting results are reported between trials.
The major strength of the above presented conclusions is that they
are based (with the exception of germline EGFR polymorphisms)
on data derived from large randomised phase III trials. On the
other hand, it should be noted that molecular analyses derived
from placebo-controlled studies (BR.21 and ISEL) were retro-
spective, not preplanned and restricted to patient subsets with
available samples and thus likely to be biased (McShane et al,
2005). Therefore, all results based on these trials should be
considered exploratory (Zhu et al, 2008). On the contrary,
chemotherapy-controlled trials (INTEREST, IPASS) had a pro-
spective preplanned biomarker analysis. Furthermore, conflicting
results about the predictive role of EGFR gene copy number could
be explained by possible biological differences between early (first
line or maintenance) vs late (second and third line) settings. The
role of EGFR mutations was confirmed in three phase III trials
specially designed for the population of patients treated in the
first-line setting (Maemondo et al, 2010; Mitsudomi et al, 2010;
Zhou et al, 2010).
An important issue is when to use EGFR TKI in patients who
have EGFR mutations in their tumours – should these agents be
administered as first-line, maintenance or as second/third-line
treatment? Only comparative data exist to answer this question; no
prospective study has been specifically designed to address this
issue and cross-study comparisons are not reliable. It is unlikely
that a clinical trial will be designed to answer this question, given
the large number of patients who will be needed. Given that there
is unquestionable benefit in terms of PFS, RR and quality of life in
the first-line setting, and that only a subgroup of patients will be
suitable for second-line treatment, EGFR TKIs should be
recommended in NSCLC patients harbouring EGFR mutations
for first-line treatment (D’Addario et al, 2010).
Another important issue is whether treatment with EGFR TKIs
should be denied to patients with tumours showing wild-type
EGFR gene. The BR.21 study reported that both groups (tumours
having EGFR mutations or wild-type EGFR) derive a survival
benefit from treatment with erlotinib compared with placebo,
although the effect of erlotinib was much greater in patients with
EGFR-mutated tumours (Shepherd et al, 2005). A similar
observation was reported in the SATURN trial (Cappuzzo et al,
2010a). Based on the results of this and other trials, EGFR TKI
treatment should not be confined to patients harbouring EGFR
mutations, although the smaller benefit in patients with EGFR
wild-type tumours should be taken into account in pharmacoeco-
nomic analyses to guide reimbursement decisions. It is likely that a
combination of markers, such as K-RAS mutations or other as yet
unidentified markers, will be used in future to identify patients
who will not benefit from EGFR TKI therapy.
An important concern is the feasibility of large-scale screening
of NSCLC patients for EGFR mutations. A study from the Spanish
Lung Cancer Group reported the screening of 42000 NSCLC
patients and found mutations in 350 patients (16.6%; Rosell et al,
2009). Median PFS and OS for 217 patients who received erlotinib
were 14 and 27 months, respectively. New techniques of EGFR
mutation testing, in particular IHC with antibodies constructed
against abnormal EGFR proteins as a result of gene mutations,
should facilitate large-scale testing (Kitamura et al, 2010).
The evolution of our knowledge of biomarkers to guide treatment
in NSCLC patients treated with EGFR inhibitors came in parallel to
the clinical trials testing these agents. This knowledge should serve
as a lesson in the current development of other agents in NSCLC,
where many trials do not meet their end points because of a
questionable clinical benefit in unselected populations. Rational
drug development, based on profound understanding of tumour
biology, a drug’s mechanism of action and clinical implications of
patient selection, is hoped to impact on the current poor treatment
outcomes of NSCLC patients.
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